SITBASE

SITBASE is a uniquely comprehensive phlebotonic-venoprotective formulation combining four active agents that address haemorrhoid pathophysiology through complementary vascular, anti-inflammatory, and mucosal-protective mechanisms.

Euphorbia prostrata 100mg is a traditional plant extract with evidence-based proctological utility. It contains terpenoids and flavonoids that exert multiple anti-haemorrhoidal actions: reduction of venous congestion through venotonic activity (increasing venous smooth muscle tone), anti-inflammatory prostaglandin inhibition (reducing peri-haemorrhoidal tissue oedema), and local haemostatic effects (reducing bleeding from haemorrhoidal tissue). Clinical studies specifically in haemorrhoid management have demonstrated statistically significant reductions in bleeding, pain, and prolapse scores compared to placebo.

Calcium Dobesilate 500mg is a synthetic calcium salt with potent vascular protective properties. It inhibits vascular permeability by blocking bradykinin, serotonin, and prostaglandin-mediated increases in capillary permeability — reducing the plasma extravasation responsible for haemorrhoidal oedema and congestion. Calcium dobesilate also normalises blood viscosity (reducing erythrocyte aggregation and improving microvascular flow), decreases platelet aggregation, and has anti-thrombotic activity in the microvasculature — collectively reducing haemorrhoidal venous stasis and the inflammatory tissue injury it causes.

Diosmin 450mg + Hesperidin 50mg (together 500mg micronised purified flavonoid fraction — MPFF): This standardised citrus flavonoid combination is the most extensively studied phlebotonic agent in haemorrhoid management. Diosmin and hesperidin inhibit noradrenaline-induced venous smooth muscle degradation, increasing venous tone and reducing venous capacitance — the fundamental mechanism of haemorrhoidal prolapse. They also inhibit prostaglandin and thromboxane synthesis, reduce leukocyte adhesion to venous endothelium, and decrease capillary permeability — providing anti-inflammatory, anti-oedematous, and microvascular protective effects that complement calcium dobesilate's mechanism.

SITBASE is indicated for haemorrhoidal disease and chronic venous insufficiency of the lower GI tract where the combined phlebotonic-anti-inflammatory-venoprotective approach of its four-component formulation provides superior outcomes to single-agent therapy.

Haemorrhoids — All Grades (Primary Indication): Grade I–III symptomatic haemorrhoids (bleeding, pain, prolapse, pruritus) — the primary and most evidence-supported indication for this product class. SITBASE addresses all haemorrhoidal symptom dimensions: Euphorbia prostrata reduces bleeding; calcium dobesilate reduces oedema and congestion; MPFF (diosmin + hesperidin) reduces prolapse and venous stasis.

Acute Haemorrhoidal Crisis: Acute flares with severe bleeding, thrombosis risk, and oedema — the combination's multi-mechanism action provides more rapid and complete acute symptom control than single-agent phlebotonic therapy.

Post-Haemorrhoidectomy: Accelerated healing and reduced post-surgical oedema, pain, and bleeding risk after haemorrhoidal procedures.

Chronic Venous Insufficiency: Lower limb venous insufficiency — calcium dobesilate and MPFF have established evidence in CVI management beyond haemorrhoids.

Chronic Anal Fissure: Venoprotective and anti-inflammatory effects reduce the chronic vascular engorgement that perpetuates anal fissure healing failure.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.